AbbVie Inc ABBV has announced new data from a Phase 2 trial of navitoclax combined with ruxolitinib in myelofibrosis patients at the American Association for Cancer Research annual meeting.
- The results presented at AACR 2022 were from REFINE Phase 2 trial, which included patients with myelofibrosis who had progressed on or had a suboptimal response to at least 12 weeks of ruxolitinib monotherapy.
- In the exploratory analysis of 32 evaluable patients, 12 (38%) had a ≥1 grade improvement in bone marrow fibrosis (BMF).
- For driver gene variant allele frequency (VAF) reduction, 26 patients were evaluable, and 6 (23%) achieved a ≥20% reduction at week 24.
- Five patients achieved both BMF and VAF responses.
- Median overall survival (OS) for all patients was not reached.
- For patients who had a ≥1 grade improvement, BMF median OS was not reached compared with 28.5 months for patients who did not experience an improvement.
- Similarly, median OS was also not reached for patients who achieved a ≥20% driver gene VAF reduction versus 28.5 months for patients who did not.
- All 34 patients (100%) experienced at least one adverse event (AE), and 15 (44%) experienced a serious adverse event (SAE).
- Price Action: ABBV shares are down 0.11% at $169.85 during the market session on the last check Tuesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.